Periungual and subungual pyogenic granuloma following anti-TNF-α therapy: is it the first case?

Patruno, Cataldo; Balato, Nicola; Cirillo, Teresa; Napolitano, Maddalena; Ayala, Fabio

doi:10.1111/dth.12022

Cited by 9 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2013, the development of multiple periungual and subungual PGs was reported after 3 months of therapy with etanercept in a 20-year-old man with psoriatic arthritis while onycholysis is a common adverse event of adalimumab. 19 It has been speculated that agents targeting tumour necrosis factor (TNF)-α might induce PG modulating the production of cytokines that ultimately lead to up-regulation of VEGF. 19 A description of rituximab-induced PG was published in 2010: a 73-year-old woman, on chronic treatment with glucocorticoids and methotrexate for rheumatoid arthritis, presented with numerous PG lesions 2 months after receiving the second course of rituximab.…”

Section: Discussionmentioning

confidence: 99%

Belimumab-induced periungual pyogenic granulomas: A case report

Chighizola,

Suardi,

Marino

et al. 2024

Lupus

View full text Add to dashboard Cite

Pyogenic granuloma (PG) is a benign vascular neoformation, presenting as a painful red nodule on the skin, mucosa or nail apparatus. It is usually related to local complications such as bleedings and superinfections. The etiology of PG remains still unclear, and several triggers can lead to its formation. In case of multiple lesions, systemic conditions and drugs remain the main causes. Antineoplastic treatments, retinoids, antiretrovirals, hormones and anticonvulsants are frequently implicated in PG formation. In literature, PG has been rarely described in the course of biological treatment due to rheumatological disease. The present case report describes the development of polydactolous PGs in a 21-year-old woman with juvenile systemic lupus erythematosus (jSLE) during treatment with belimumab, a monoclonal antibody directed against BlyS. The clinical presentation, in particular the timing and the multiplicity of the lesions, and the improvement after belimumab discontinuation allowed us to consider PG as drug-induced. This case highlights the importance of considering PG as a potential complication of rheumatologic treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Belimumab-induced periungual pyogenic granulomas: A case report

Chighizola,

Suardi,

Marino

et al. 2024

Lupus

View full text Add to dashboard Cite

show abstract

“…TNF-α is able to induce keratinocyte expression, which, in turn, up-regulate VEGF production. The authors report a case of lobular capillary hemangioma due to an anti-TNF-α drug 8 …”

Section: Discussionmentioning

confidence: 99%

Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation

Silva

Guimarães

Xavier

et al. 2019

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Lobular capillary hemangioma or pyogenic granuloma is a benign vascular tumor of the skin or mucous membranes. Most patients present a single lesion. It manifests clinically as an erythematous, friable, and fast-growing tumor. This report details a case with exuberant presentation in a patient with ankylosing spondylitis, using adalimumab. Factors triggering pyogenic granuloma are not well known. They may spontaneously regress, but most require treatment.

show abstract

“…PG can occur secondarily to acute or chronic local trauma, infection, drugs, i.e., retinoids, antiretrovirals, antineoplastics and pregnancy [1]. A case of periungual PG due to an anti-TNF-alpha drug (etanercept) has been described by Patruno et al [3]. …”

Section: Discussionmentioning

confidence: 99%

Periungual Pyogenic Granuloma: The Importance of the Medical History

Alessandrini

Bruni

Starace

et al. 2015

Skin Appendage Disord

View full text Add to dashboard Cite

Pyogenic granuloma (PG) is a common, benign vascular proliferation that can arise on the skin or subcutaneous tissue. It is more frequent in the early decades of life, and the most common locations are the digits of both hands and feet. The most common cause of periungual PG is drug intake, but many other trigger factors have been described in the literature. Treatment should be chosen according to the cause. We describe 2 particular cases of periungual PG in which the clinical history has been fundamental. In the first case, there was an underlying hand eczema, and in the second case, a foreign body was present.

show abstract

Periungual and subungual pyogenic granuloma following anti-TNF-α therapy: is it the first case?

Cited by 9 publications

References 8 publications

Belimumab-induced periungual pyogenic granulomas: A case report

Belimumab-induced periungual pyogenic granulomas: A case report

Lobular capillary hemangioma in a patient with ankylosing spondylitis using adalimumab: an exuberant presentation

Periungual Pyogenic Granuloma: The Importance of the Medical History

Contact Info

Product

Resources

About